Clinical Trials
130 trialsSelvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Case Comprehensive Cancer Center
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
Institute of Hematology & Blood Diseases Hospital, China
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
DREAMM 13
GlaxoSmithKline
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Thomas Jefferson University
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
Situs Cancer Research Center
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
Case Comprehensive Cancer Center
AcTRESS
Jules Bordet Institute
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
University of Pittsburgh
HMvax-Regist
Wake Forest University Health Sciences
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
University of Arkansas
Marizomib Central Nervous System (CNS)
Dana-Farber Cancer Institute
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Washington University School of Medicine
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Emory University
ALUMMINATE
Celgene
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
National Cancer Institute (NCI)
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Jonsson Comprehensive Cancer Center
AHCT
Case Comprehensive Cancer Center
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma
Fred Hutchinson Cancer Center
An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Soochow University
MM FPBMC
University of Virginia
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
LaNova Medicines Limited
PENTI-MIDAS
Nantes University Hospital
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Canadian Myeloma Research Group
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
ModernaTX, Inc.
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Shanghai Pudong Hospital
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Alliance Foundation Trials, LLC.
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Hackensack Meridian Health
SLAM
Karyopharm Therapeutics Inc
SCORE
Karyopharm Therapeutics Inc
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Indiana University
ProxiMMity-1
Amgen
Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
University of California, San Francisco
A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma
Memorial Sloan Kettering Cancer Center
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Academic and Community Cancer Research United
Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma
Bristol-Myers Squibb
Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma
Bioray Laboratories
ESdRRMM
Tulane University
US MM-7
Takeda
Study of Dara-Pembro for Multiple Myeloma Patients
Wake Forest University Health Sciences
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
Wake Forest University Health Sciences
Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma
Washington University School of Medicine
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Indiana University
COAST
Oncopeptides AB
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
Collecting and Storing Blood Samples From Patients With Cancer
Rutgers, The State University of New Jersey
Immuno-POWER
Big Ten Cancer Research Consortium